Health Canada approves Dupixent (dupilumab) as the first biologic for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years

23 February 2021 - Dupixent is the only biologic medicine approved to treat atopic dermatitis for this patient population. ...

Read more →

Health Canada approves ALK's Ragwitek sublingual allergy immunotherapy tablets for paediatric patients with ragweed allergy

22 December 2020 - With the indication expanded to paediatric patients, ALK Canada now provides adults and children a SLIT tablet ...

Read more →

Health Canada Approves Brivlera (brivaracetam) to treat partial-onset seizures in paediatric epilepsy patients

29 July 2020 - Health Canada's approval of Brivlera provides paediatric epilepsy patients with a treatment option which can be initiated ...

Read more →

Health Canada approves fast-acting mealtime insulin, Fiasp, for children with diabetes

9 March 2020 - Health Canada also expands Fiasp approval to include insulin infusion pumps. ...

Read more →

Health Canada approves Dupixent as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis

27 September 2019 - Dupixent can significantly reduce the constant itch and improve the skin's overall condition. ...

Read more →

Federal health minister announces new treatment options for children

25 July 2019 - Health Minister Ginette Petitpas Taylor made the announcement at Health Sciences North in Sudbury on Thursday. ...

Read more →

Health Canada has authorised Vyvanse (lisdexamphetamine dimesylate), the first and only, chewable tablet for the treatment of attention deficit/hyperactivity disorder

10 July 2019 - Vyvanse offers an additional option for patients who prefer the convenience of a chewable tablet, or who ...

Read more →

AbbVie's Humira (adalimumab) approved by Health Canada to treat paediatric patients with chronic non-infectious anterior uveitis

20 February 2019 - The approval marks Humira as the only approved biologic treatment option in Canada for paediatric patients from ...

Read more →

Health Canada grants market authorisation for Orkambi (lumacaftor/ivacaftor) for children with cystic fibrosis aged 2 to 5 years old with most common form of the disease

13 December 2018 - Orkambi is the first medicine in Canada to treat the underlying cause of cystic fibrosis in young ...

Read more →

Alberta boy with thyroid cancer runs, plays after taking U.S. approved drug

5 December 2018 - Health Canada is considering approving the oral treatment, larotrectinib. ...

Read more →

Health Canada approves Tresiba for children with Type 1 diabetes

1 October 2018 - Rates of Type 1 diabetes among children and youth on the rise globally. ...

Read more →

Sunovion announces Health Canada approval of Aptiom (eslicarbazepine acetate) as adjunctive therapy for the treatment of partial-onset seizures in adolescents and children above six years of age

19 September 2018 - Sunovion Pharmaceuticals today announced that Health Canada approved the supplemental new drug submission to expand the ...

Read more →

Pediapharm receives Health Canada approval for Cuvposa

1 November 2017 - Pediapharm is very pleased to announce Health Canada's notice of compliance (approval) for Cuvposa (Glycopyrrolate oral ...

Read more →

Workshop: addressing unmet needs of children with pulmonary arterial hypertension

6 June 2017 - The EMA, the United States FDA and Health Canada are co-organising a workshop to discuss the ...

Read more →